18F-FDG PET/CT在多发性骨髓瘤及其他浆细胞疾病诊断与管理中的作用:国际骨髓瘤工作组共识声明
国际骨髓瘤工作组发布共识,推荐18F-FDG PET/CT用于多发性骨髓瘤(初诊及复发难治)的检查,因其评估骨损伤敏感性及特异性较高、可检测髓外病变并提供预后信息。共识指出,当全身MRI无法进行时,PET/CT对疑似孤立性浆细胞瘤的诊断是必需的;当全身X线阴性且全身MRI不可用时,用于区分冒烟型与活动性多发性骨髓瘤。PET/CT是目前首选的功成像方式,用于评估和监测治疗对骨髓瘤细胞代谢的影响。
要点
- 18F-FDG PET/CT可考虑用于初诊及复发难治多发性骨髓瘤的检查,评估骨损伤并检测髓外增殖性克隆浆细胞。
- 疑似孤立性浆细胞瘤且全身MRI无法进行时,18F-FDG PET/CT是确认诊断的必需检查。
- 全身X线阴性且全身MRI不可用时,PET/CT用于区分冒烟型与活动性多发性骨髓瘤。
核心结论
- 18F-FDG PET/CT可考虑作为初诊及复发难治多发性骨髓瘤的有价值检查工具,评估骨损伤敏感性及特异性较高、检测髓外增殖性克隆浆细胞并提供重要预后信息;在特定条件下是确认孤立性浆细胞瘤诊断及区分冒烟型与活动性骨髓瘤的必需或首选功能成像方式。
研究设计与样本
- 国际骨髓瘤工作组(International Myeloma Working Group)发布的共识声明,旨在为多发性骨髓瘤及其他浆细胞疾病(包括冒烟型多发性骨髓瘤和孤立性浆细胞瘤)患者中18F-FDG PET/CT的最佳使用提供推荐。
关键影像表现/征象
- 18F-FDG PET/CT可评估骨损伤,敏感性及特异性相对较高。
- 18F-FDG PET/CT可检测髓外增殖性克隆浆细胞部位。
- FDG亲和力变化可较MRI扫描更早评估治疗反应,并可预测结局,尤其对适合接受自体干细胞移植的患者。
- 18F-FDG PET/CT可与基于骨髓的敏感技术联合,检测骨髓内外的微小残留病(MRD),帮助识别影像学MRD阴性患者。
诊断标准与关键数值
- 疑似孤立性浆细胞瘤:当全身MRI无法进行时,使用18F-FDG PET/CT确认诊断是必需的。
- 区分冒烟型与活动性多发性骨髓瘤:当全身X线(WBXR)阴性且全身MRI不可用时,使用18F-FDG PET/CT。
- 基于18F-FDG PET/CT区分代谢活跃与不活跃疾病的能力,该技术目前是评估和监测治疗对骨髓瘤细胞代谢影响的首选功能成像方式。
临床应用与阅片要点
- 18F-FDG PET/CT可考虑用于初诊及复发难治多发性骨髓瘤患者的检查。
- 疑似孤立性浆细胞瘤且全身MRI无法进行时,18F-FDG PET/CT是确认诊断的必需检查。
- 全身X线阴性且全身MRI不可用时,可用18F-FDG PET/CT区分冒烟型与活动性多发性骨髓瘤。
- 18F-FDG PET/CT目前是评估和监测治疗对骨髓瘤细胞代谢影响的首选功能成像方式,FDG亲和力变化可较MRI更早评估治疗反应。
- 18F-FDG PET/CT可与基于骨髓的敏感技术联合检测骨髓内外MRD,帮助识别影像学MRD阴性患者。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
The International Myeloma Working Group consensus aimed to provide recommendations for the optimal use of 18fluorodeoxyglucose (18F-FDG) PET/CT in patients with multiple myeloma and other plasma cell disorders, including smouldering multiple myeloma and solitary plasmacytoma. 18F-FDG PET/CT can be considered a valuable tool for the work-up of patients with both newly diagnosed and relapsed or refractory multiple myeloma because it assesses bone damage with relatively high sensitivity and specificity, and detects extramedullary sites of proliferating clonal plasma cells while providing important prognostic information. The use of 18F-FDG PET/CT is mandatory to confirm a suspected diagnosis of solitary plasmacytoma, provided that whole-body MRI is unable to be performed, and to distinguish between smouldering and active multiple myeloma, if whole-body X-ray (WBXR) is negative and whole-body MRI is unavailable. Based on the ability of 18F-FDG PET/CT to distinguish between metabolically active and inactive disease, this technique is now the preferred functional imaging modality to evaluate and to monitor the effect of therapy on myeloma-cell metabolism. Changes in FDG avidity can provide an earlier evaluation of response to therapy compared to MRI scans, and can predict outcomes, particularly for patients who are eligible to receive autologous stem-cell transplantation. 18F-FDG PET/CT can be coupled with sensitive bone marrow-based techniques to detect minimal residual disease (MRD) inside and outside the bone marrow, helping to identify those patients who are defined as having imaging MRD negativity.
引用
- Cavo M, Terpos E, Nanni C, et al. Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group. Lancet Oncol. 2017. PMID: 28368259. doi:10.1016/S1470-2045(17)30189-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。